DiogenX
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
Total raised
€32M
€32,000,000
Funding rounds
2
Investors
6
distinct backers
Active since
2020-06
latest 2023-05
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood36
base rate 44% for Series A
- ▼ Overdue vs cohort gap
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-05-10 | Series A | €28M | AdBio partners,Boehringer Ingelheim Venture Fund,Eli lilly and company,JDRF T1D Fund,Omnes Capital,Roche Venture Fund | View deal → |
| 2020-06-16 | Seed | €4.5M | — | View deal → |
Investors
6Related news
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software